Literature DB >> 25712839

Incidence, risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma: a prospective cohort study.

J F Hao, L W Zhang, J X Bai, Y J Li, J N Liu, X L Zhang, J M Han, X Li, H Jiang1, N Cao2.   

Abstract

BACKGROUND: Transcatheter arterial chemoembolization (TACE) is an effective first-line therapy for intermediate stage hepatocellular carcinoma (HCC). Acute renal injury may be induced after transarterial chemoembolization because of iodinated radiocontrast medium, but its incidence, risk factors, and prognosis remain unclear. PATIENTS AND METHODS: This prospective study enrolled 166 HCC patients with a total of 316 TACE treatments. The incidence, risk factors, and prognosis of acute kidney injury (AKI) were examined.
RESULTS: The incidence of post-TACE AKI was 21.84% (69/316) according to Barrett and Parfrey criteria, whereas 7.59% (24/316) according to acute kidney injury network (AKIN) criteria. Multivariate logistic regression analysis showed that serum total bilirubin (TB) (>13.5 μmol/L; odds ratio [OR]: 1.871 95% confidence interval [CI]: 1.044-3.352; P = 0.035) and hemoglobin (HGB) level (<120 g/L; OR: 1.823, 95% CI: 1.019-3.264; P = 0.043) were associated with the development of AKI after TACE procedure in accordance to Barrett and Parfrey criteria. Meanwhile, age (>55 years; OR: 3.456, 95% CI: 1.107-10.790; P = 0.033), post-TACE AKI history (OR: 7.108, 95% CI: 1.387-36.434, P = 0.019), and serum aminotransferase level (>55 U/L; OR: 4.420, 95% CI: 1.792-10.906; P = 0.001) were associated with the development of AKI after TACE procedure in accordance to AKIN criteria. Total hospitalization cost was significantly higher (P = 0.034) in the patients with AKI after TACE procedure according to Barrett and Parfrey criteria. A post-TACE AKI diagnosis was associated with mortality in any definition used (P = 0.034 and P = 0.001 for Barrett and Parfrey and AKIN criteria, respectively).
CONCLUSION: The present study showed that the incidence of post-TACE AKI was high in HCC patients (i.e., 7.59-21.84%) depending on criteria used. HGB (<120 g/L), serum TB (>13.5), and aminotransferase level (>55 U/L), age (>55 years) and post-TACE AKI history may be predictors of post-TACE AKI in HCC patients. The development of post-TACE AKI was associated with the risk of renal replacement treatment, prolonged renal insufficiency, or mortality according to AKIN criteria.

Entities:  

Mesh:

Year:  2015        PMID: 25712839     DOI: 10.4103/0019-509X.151984

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  3 in total

1.  Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.

Authors:  Mari Aoe; Takafumi Kanemitsu; Takamasa Ohki; Satoru Kishi; Yoshiyasu Ogura; Yuto Takenaka; Toyohiro Hashiba; Hiroko Ambe; Emi Furukawa; Yu Kurata; Masahiro Ichikawa; Ken Ohara; Tomoko Honda; Satoshi Furuse; Katsunori Saito; Nobuo Toda; Naobumi Mise
Journal:  Clin Exp Nephrol       Date:  2019-06-10       Impact factor: 2.801

2.  Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Won Sohn; Cheol Bae Ham; Nam Hee Kim; Hong Joo Kim; Yong Kyun Cho; Woo Kyu Jeon; Byung Ik Kim
Journal:  PLoS One       Date:  2020-12-14       Impact factor: 3.240

Review 3.  Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.

Authors:  Hsuan Yeh; Chung-Cheng Chiang; Tzung-Hai Yen
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.